Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.

Autor: Birtas Atesoglu E; Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey., Gulbas Z; Division of Hematology, Anadolu Medical Center, Kocaeli, Turkey., Uzay A; Division of Hematology, Acibadem Atakent Hospital, Istanbul, Turkey., Ozcan M; Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey., Ozkalemkas F; Department of Internal Medicine, Division of Hematology, Uludag University Medical Faculty, Bursa, Turkey., Dal MS; Division of Hematology, Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara, Turkey., Kalyon H; Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey., Akay OM; Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey., Deveci B; Division of Hematology, Medstar Hospital, Antalya, Turkey., Bekoz H; Department of Internal Medicine, Division of Hematology, Medipol University Medical Faculty, Istanbul, Turkey., Sevindik OG; Department of Internal Medicine, Division of Hematology, Medipol University Medical Faculty, Istanbul, Turkey., Toptas T; Department of Internal Medicine, Division of Hematology, Marmara University Medical Faculty, Istanbul, Turkey., Yilmaz F; Department of Internal Medicine, Division of Hematology, Marmara University Medical Faculty, Istanbul, Turkey., Koyun D; Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey., Alkis N; Division of Hematology, Bursa City Hospital, Bursa, Turkey., Alacacioglu I; Department of Internal Medicine, Division of Hematology, Dokuz Eylul University Medical Faculty, Izmir, Turkey., Sonmez M; Department of Internal Medicine, Division of Hematology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey., Yavasoglu I; Department of Internal Medicine, Division of Hematology, Adnan Menderes University Medical Faculty, Aydin, Turkey., Tombak A; Department of Internal Medicine, Division of Hematology, Mersin University Medical Faculty, Mersin, Turkey., Mehtap O; Department of Internal Medicine, Division of Hematology, Kocaeli University Medical Faculty, Kocaeli, Turkey., Kurnaz F; Division of Hematology, Kocaeli Medicalpark Hospital, Kocaeli, Turkey., Yuce OK; Department of Internal Medicine, Division of Hematology, Akdeniz University Medical Faculty, Antalya, Turkey., Karakus V; Division of Hematology, Antalya Research and Training Hospital, Antalya, Turkey., Turgut M; Department of Internal Medicine, Division of Hematology, Ondokuzmayıs University Medical Faculty, Samsun, Turkey., Kurekci DD; Department of Internal Medicine, Division of Hematology, Ondokuzmayıs University Medical Faculty, Samsun, Turkey., Ayer M; Division of Hematology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey., Keklik M; Department of Internal Medicine, Division of Hematology, Erciyes University Medical Faculty, Kayseri, Turkey., Buyuktas D; Division of Hematology, V.K.V. American Hospital, Istanbul, Turkey., Ozbalak M; Division of Hematology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey., Ferhanoglu B; Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.

Publikováno v: Hematological oncology [Hematol Oncol] 2023 Oct; Vol. 41 (4), pp. 663-673. Date of Electronic Publication: 2023 May 22.

Daratumumab Monotherapy Among Heavily Pretreated Patients With

Autor: Beksac, M, Aydin, Y, Goker, H, Turgut, M, Besisik, SK, Cagirgan, S, Tuglular, T, Vural, F, Yagci, M, Alacacioglu, I, Aytan, P, Goksoy, HS, Gulbas, Z, Gunes, AK, Gurkan, E, Hacioglu, SK, Karti, SS, Kaynar, L, Ozdogu, H, Paydas, S, Solmaz, S, Sonmez, M, Tekgunduz, E, Yildirim, R, Ilhan, O

The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3566::24a32a3cac281d399e675f138df50667

Turkish Hematology Research and Education Group (ThREG)-TMA01 study

Autor: Tekgunduz, E, Yilmaz, M, Erkurt, MA, Kiki, I, Kaya, AH, Kaynar, L, Alacacioglu, I, Cetin, G, Ozarslan, I, Kuku, I, Sincan, G, Salim, O, Namdaroglu, S, Karakus, A, Karakus, V, Altuntas, F, Sari, I, Ozet, G, Aydogdu, I, Okan, V, Kaya, E, Yildirim, R, Yildizhan, E, Ozgur, G, Ozcebe, OI, Payzin, B, Akpinar, S, Demirkan, F

Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue isc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3566::df58fe5c7724f80d3d0797c845667a2f
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/24537

A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Autor: Gemici A; Department of Hematology, Medipol University, Istanbul, Turkey. Electronic address: inci.alacaciogl@deu.edu.tr., Ozkalemkas F; Department of Hematology, Uludağ University, Bursa, Turkey., Dogu MH; Department of Hematology, Istinye University, Istanbul, Turkey., Tekinalp A; Department of Hematology, Necmettin Erbakan University, Konya, Turkey., Alacacioglu I; Department of Hematology, Dokuz Eylul University, Izmir, Turkey., Guney T; Department of Hematology, University of Medical Sciences, Ankara City Hospital, Ankara, Turkey., Ince I; Division of Hematology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey., Geduk A; Department of Hematology, Kocaeli University, Kocaeli, Turkey., Cagliyan GA; Department of Hematology, Pamukkale University, Denizli, Turkey., Maral S; Division of Hematology, Diskapi Training and Research Hospital, Ankara, Turkey., Serin I; Division of Hematology, Istanbul Training and Research Hospital, Istanbul, Turkey., Gunduz E; Department of Hematology, Osman Gazi University, Eskisehir, Turkey., Karakus V; Department of Hematology, Alaaddin Keykubat University, Alanya, Turkey., Bekoz HS; Department of Hematology, Medipol University, Istanbul, Turkey., Eren R; Division of Hematology, Bozyaka Training and Research Hospital, Izmir, Turkey., Pinar IE; Department of Hematology, Uludağ University, Bursa, Turkey., Gunes AK; Department of Hematology, University of Medical Sciences, Ankara City Hospital, Ankara, Turkey., Sargın FD; Department of Hematology, Medipol University, Istanbul, Turkey., Sevindik OG; Department of Hematology, Medipol University, Istanbul, Turkey.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Aug; Vol. 21 (8), pp. e686-e692. Date of Electronic Publication: 2021 Apr 20.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.